Clinical trials: Clear Cell Renal Cancer
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
This phase I trial studies the side effects and the best dose of sunitinib malate when given together with bevacizumab in treating patients with kidney cancer or advanced solid malignancies.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
- Trial name
- NCT01243359
- Testing
- sunitinib malate, bevacizumab, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Carcinoma, Phase 1
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
- Conditions
- Clear Cell Carcinoma, Phase 1, Growth Factor
- Trial name
- NCT07072234
- Testing
- Lymphodepleting chemotherapy, Dexamethasone, Fludarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma
ABEMA Alone or in COMBO With MK-6482
This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT04627064
- Testing
- Abemaciclib, MK-6482
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
This randomized phase II trial studies how well pazopanib hydrochloride with or without ascorbic acid work in treating patients with kidney cancer that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03334409
- Testing
- Ascorbic Acid, Pazopanib Hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Academic and Community Cancer Research United
Kidney Cancer
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00853125
- Testing
- therapeutic allogeneic lymphocytes, sunitinib malate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
- Trial name
- NCT06805825
- Testing
- NN3201
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Novelty Nobility, Inc.
Kidney Cancer, Renal Cell Carcinoma
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor…
- Conditions
- Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04623502
- Testing
- 13C-Glucose, 13C-Acetate, 13C-Lactate
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Kidney Cancer
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00301990
- Testing
- aldesleukin, bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.
To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).
- Trial name
- MDX1411-01 (NCT00656734)
- Testing
- MDX 1411
- Where
- 7 sites in United States
- Volunteers
- 27 people
- Sponsor
- Bristol-Myers Squibb
Clear Cell Renal Carcinoma
89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE
The study is designed to explore the safety and tolerability as well as diagnostic 89Zr-girentuximab for imaging CCRC by PET/CT.
- Trial name
- NCT03556046
- Testing
- 89Zr-Girentuximab
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
PSMA Therapy and Immunotherapy in Kidney Cancer
This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell…
- Trial name
- NCT06361810
- Testing
- Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Renal Cell Carcinoma
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed.
- Trial name
- NCT01182142
- Testing
- Capecitabine
- Where
- Russia
- Volunteers
- 51 people
- Sponsor
- Kidney Cancer Research Bureau
Renal Cell Carcinoma
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
- Trial name
- NCT03294083
- Testing
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 95 people
- Sponsor
- SillaJen, Inc.
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib…
- Trial name
- CANTATA (NCT03428217)
- Testing
- CB-839, Cabozantinib
- Where
- 133 sites in United States, Australia and 6 more
- Volunteers
- 444 people
- Sponsor
- Calithera Biosciences, Inc
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer
- Trial name
- ZAMBONI (NCT07043608)
- Testing
- Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kelly Fitzgerald, MD
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00425386
- Testing
- erlotinib hydrochloride, sunitinib malate, biopsy
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
Kidney Cancer
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900536
- Testing
- mutation analysis, polymorphism analysis, protein expression analysis
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.
- Trial name
- NCT00944905
- Testing
- MDX-1203
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0)…
- Conditions
- Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
- Trial name
- NCT07389629
- Testing
- QL1706 Combined With Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University